ArticleWound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society
Metformin Enhances the Pro-Regenerative Function of Human Adipose-Derived Stromal Cells for Diabetic Wound Healing.
Article in Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Metformin Enhances the Pro-Regenerative Function of Human Adipose-Derived Stromal Cells for Diabetic Wound Healing.Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair SocietyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Chronic wounds associated with diabetes remain a major challenge due to impaired angiogenesis, reduced fibroblast activity and dysfunction of regenerative cells. Adipose-derived mesenchymal stromal cells (ASCs) represent a promising therapeutic option; however, their regenerative potential is limited under hyperglycaemic conditions. This study investigated whether metformin could enhance ASC function and improve their therapeutic potential for tissue regeneration. Transcriptomic analysis of wound tissue identified pathways associated with angiogenesis, inflammation, extracellular matrix remodelling and cell survival, including PI3K-AKT, JAK-STAT and AGE-RAGE signalling. Functionally, metformin increased ASC proliferation in a concentration-dependent manner and promoted sustained cell expansion over time. Metformin-treated ASCs also enhanced fibroblast migration in a co-culture system, indicating improved paracrine pro-reparative signalling. Metformin further increased the secretion of angiogenic factors, including vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF), supporting a pro-angiogenic secretory profile. Metformin enhanced CD31 expression and tube formation capacity of ASCs under normoglycemic conditions, particularly in combination with VEGF; however, these effects were attenuated under high-glucose conditions. Additionally, metformin improved ASC adhesion to small intestinal submucosa (SIS) scaffolds and supported endothelial marker expression in a three-dimensional biomaterial environment. Collectively, these findings demonstrate that metformin promotes a pro-regenerative ASC phenotype characterized by enhanced proliferation, paracrine signalling, endothelial-associated responses and scaffold integration. However, hyperglycaemic conditions partially impair these effects, highlighting the influence of metabolic stress on regenerative responses. Overall, metformin preconditioning represents a promising strategy to enhance ASC-based therapies for chronic and diabetic wound healing.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.